dimethyl 5-((-2-((tert-butyloxy)carbonyl)amino)ethoxy)benzene-1,3-dicarboxylate | 198700-45-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: dimethyl 5-((-2-((tert-butyloxy)carbonyl)amino)ethoxy)benzene-1,3-dicarboxylate
• 英文别名: dimethyl 5-(2-(((t-butoxy)carbonyl)amino)ethoxy)benzene-1,3-dicarboxylate；5-(2-(tert-butoxycarbonylamino)ethoxy)isophthalic acid dimethyl ester；Tert-butyl 2-(3,5-di(methoxycarbonyl)phenoxy)ethylcarbamate；dimethyl 5-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethoxy]benzene-1,3-dicarboxylate
• CAS: 198700-45-7
• 化学式: C₁₇H₂₃NO₇
• 分子量: 353.372
• InChiKey: MAJVXRDYLIPPBF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  25
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  100
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  dimethyl 5-((-2-((tert-butyloxy)carbonyl)amino)ethoxy)benzene-1,3-dicarboxylate 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 生成 5-((-2-((tert-butyloxy)carbonyl)amino)ethoxy)benzene-1,3-dicarboxylic acid
  参考文献：
  名称：

  [EN] SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE
  [FR] PLATEFORMES D'ADMINISTRATION À DES MUSCLES SQUELETTIQUES ET MÉTHODES D'UTILISATION

  摘要：

  本公开涉及将有效载荷有针对性地且高效地引导至体内骨骼肌细胞的传递平台。所述传递平台包括靶向配体（例如具有亲和力的化合物，包括α-v-β-6整合素）和药代动力学/药效学（PK/PD）调节剂，以促进有效载荷传递到细胞，包括骨骼肌细胞。适用于本公开的传递平台的有效载荷包括RNAi剂，可以链接或结合到传递平台上，在体内传递时，可以抑制骨骼肌细胞的基因表达。还描述了包括骨骼肌细胞传递平台的药物组合物，以及用于治疗各种疾病和疾病的方法，其中传递治疗有效载荷至骨骼肌细胞是可取的。

  公开号：

  WO2022056269A1
• 作为产物：
  描述：

  5-羟基间苯二甲酸二甲酯 在 盐酸 、 一水合肼 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 反应 48.0h， 生成 dimethyl 5-((-2-((tert-butyloxy)carbonyl)amino)ethoxy)benzene-1,3-dicarboxylate
  参考文献：
  名称：

  Perfectly branched polyamide dendrons based on 5-(2-aminoethoxy)-isophthalic acid

  摘要：

  Perfectly branched polyamide dendrons based on 5-(2-aminoethoxy)-isophthalic acid have been synthesized up to generation 4 following the convergent approach. This involved a repetitive reaction of 5-(2-t-butoxycarbamylethoxy)-isophthalic acid with the two fold excess of 5-(2-aminoethoxy-hydrochloride)-isophthalic acid dimethyl ester and its analogs of higher generation, respectively, using activation and protection methods from the peptide chemistry. The products were characterized via elemental analysis, different spectroscopic methods, gel permeation chromatograpy, and differential scanning calorimetry. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4020(97)00978-2

文献信息

• NUCLEIC ACID CONJUGATE
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：US20190192674A1

  公开（公告）日：2019-06-27

  The present invention provides a nucleic acid conjugate in which a sugar chain ligand is bonded to an oligonucleotide via a linker, the sugar chain ligand having O-bonded mannose at its non-reducing end.

  本发明提供了一种核酸共轭物，其中糖链配体通过链接剂与寡核苷酸结合，该糖链配体在其非还原端具有O-键合的甘露糖。
• Facially amphiphilic polymers and oligomers and uses thereof
  申请人：DeGrado William F.

  公开号：US09241917B2

  公开（公告）日：2016-01-26

  The present invention discloses methods of use of facially amphiphilic polymers and oligomers, including pharmaceutical uses of the polymers and oligomers as antimicrobial agents and antidotes for hemorrhagic complications associated with heparin therapy. The present invention also discloses novel facially amphiphilic polymers and oligomers and their compositions, including pharmaceutical compositions. The present invention further discloses the design and synthesis of facially amphiphilic polymers and oligomers.

  本发明公开了利用具有两性表面活性的聚合物和寡聚物的方法，包括将这些聚合物和寡聚物用作抗微生物药物和用于肝素治疗相关的出血并发症的解毒剂的药用。本发明还公开了新颖的具有两性表面活性的聚合物和寡聚物及其组合物，包括药用组合物。本发明进一步公开了具有两性表面活性的聚合物和寡聚物的设计和合成。
• [EN] LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS<br/>[FR] CONJUGUÉS LIPIDIQUES POUR L'ADMINISTRATION D'AGENTS THÉRAPEUTIQUES
  申请人：ARROWHEAD PHARMACEUTICALS INC

  公开号：WO2022056273A1

  公开（公告）日：2022-03-17

  Disclosed herein are compounds according to Formula (I) comprising PK/PD modulators for delivery of oligonucleotide-based agents, e.g., double stranded RNAi agents, to certain cell types, such for example skeletal muscle cells, in vivo. The PK/PD modulators disclosed herein, when conjugated to an oligonucleotide-based therapeutic or diagnostic agent, such as an RNAi agent, can enhance the delivery of the composition to the specified cells being targeted to facilitate the inhibition of gene expression in those cells.

  本文公开了公式（I）中的化合物，包括PK/PD调节剂，用于将基于寡核苷酸的制剂（例如双链RNAi制剂）递送到体内某些细胞类型，例如骨骼肌细胞。本文所披露的PK/PD调节剂与基于寡核苷酸的治疗或诊断制剂（如RNAi制剂）结合后，可以增强将该组合物递送到特定的目标细胞，以促进在这些细胞中抑制基因表达。
• Facially Amphiphilic Polymers and Oligomers and Uses Thereof
  申请人：DeGrado William F.

  公开号：US20130023561A1

  公开（公告）日：2013-01-24

  The present invention discloses methods of use of facially amphiphilic polymers and oligomers, including pharmaceutical uses of the polymers and oligomers as antimicrobial agents and antidotes for hemorrhagic complications associated with heparin therapy. The present invention also discloses novel facially amphiphilic polymers and oligomers and their compositions, including pharmaceutical compositions. The present invention further discloses the design and synthesis of facially amphiphilic polymers and oligomers.

  本发明揭示了利用面部亲疏水性聚合物和寡聚物的使用方法，包括将这些聚合物和寡聚物作为抗微生物剂和用于治疗肝素治疗相关出血并发症的解毒剂的药物使用。本发明还揭示了新型的面部亲疏水性聚合物和寡聚物及其组合物，包括药物组合物。本发明还揭示了面部亲疏水性聚合物和寡聚物的设计和合成。
• Drug efflux pump inhibitor
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1652839A2

  公开（公告）日：2006-05-03

  A medicament for preventive and/or therapeutic treatment of a microbial infection having an activity of eliminating resistance of a microorganism with acquired resistance to an antimicrobial agent, which comprises as an active ingredient a compound represented by the following general formula (I), a physiologically acceptable salt thereof, or a hydrate thereof: wherein R1 and R2 independently represent hydrogen atom, a halogen atom, carboxyl group and the like; J1 represents a 5- or 6-membered heteroaromatic ring; W1 represents -CH=CH-, -C≡C-, -CH2CH2- and the like; A1 represents phenylene group, pyridinediyl group, furandiyl group and the like; G1 represents oxygen atom, carbonyl group, ethynyl group and the like; p represents an integer of from 0 to 3; G2 represents phenylene group, furandiyl group, tetrahydrofurandiyl group and the like; G3 represents -CH2- or single bond; m and n represent an integer of 0 or 1; and Q1 represents an acidic group.

  一种用于预防和/或治疗微生物感染的药物，具有消除对抗菌剂产生抗药性的微生物的抗药性的活性，其活性成分包括下式（I）所代表的化合物、其生理上可接受的盐或其水合物： 其中 R1 和 R2 分别代表氢原子、卤素原子、羧基等；J1 代表 5 或 6 元杂芳环；W1 代表 -CH=CH-、-C≡C-、- - 等；A1 代表亚苯基、吡啶二基、呋喃二基等；G1 代表氧原子、羰基、乙炔基等；p 代表 0 至 3 的整数；G2 代表亚苯基、呋喃二基、四氢呋喃二基等；G3 代表 -CH2- 或单键；m 和 n 代表 0 或 1 的整数；以及 Q1 代表酸性基团。